Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Group 1 - Anixa Biosciences, Inc. is participating in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at Nasdaq World Headquarters in New York City [1][2] - Mike Catelani, President and CFO of Anixa, will present and be available for one-on-one meetings during the conference [1][2] - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] Group 2 - The company's vaccine portfolio includes vaccines for breast and ovarian cancer developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - Anixa's business model involves partnerships with renowned research institutions at all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [2]